![]() ![]() ET.īridgeBio will host an investor webcast on March 22 at 8:00 a.m. The presentations will be on display in ENDO 2021’s virtual poster hall starting on March 20 at 11:00 a.m. The data are featured in an ePoster presentation titled ‘The Effects of Encaleret (CLTX-305) on Mineral Physiology in ADH1 Demonstrate Proof-of-Concept: Early Results from an Ongoing Phase 2B, Open-Label, Dose-Ranging Study.’ If the development program is successful, encaleret could be the first approved therapy for ADH1, a condition caused by gain of function variants in the calcium-sensing receptor gene estimated to be carried by 12,000 individuals in the United States.įull ePoster presentation details are listed below, and the full preliminary program is available online at the ENDO 2021 website. ![]() (Nasdaq: BBIO), a clinical-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic drivers, today announced that early results from an ongoing Phase 2 proof-of-concept study of encaleret for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1) will be shared at the upcoming Endocrine Society’s 2021 Annual Meeting (ENDO 2021) taking place virtually from March 20 - 23. 24, 2021 (GLOBE NEWSWIRE) - BridgeBio Pharma, Inc.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |